Actively Recruiting
Phase III Study Comparing MRG003 Plus Pucotenlimab to Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma
Led by Lepu Biopharma Co., Ltd. · Updated on 2026-08-31
446
Participants Needed
1
Research Sites
82 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy, safety, and immune response of MRG003 combined with pucotenlimab compared to chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma. This phase III, randomized, open-label, multi-center study focuses on individuals who have previously undergone systemic therapy and have measurable disease, aiming to improve treatment options for this condition. Participants will receive either the combination of MRG003 and pucotenlimab administered as specified in the protocol, or one of three chemotherapy options selected by the investigator gemcitabine, docetaxel, or capecitabine. Chemotherapy drugs are given intravenously or orally in 21-day cycles, with specific dosing schedules for each drug. The study compares these treatments over several months. During the trial, participants will be monitored through assessments of progression-free survival and overall survival, along with objective response and disease control rates. Immunogenicity and adverse events will be tracked up to 30 days after treatment ends. The study duration may extend up to 48 months, with regular follow-ups to evaluate treatment outcomes and safety under medical supervision.
CONDITIONS
Brief Title
A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Research Team
P
Program Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here